Patients receiving neuromuscular blocking medications as part of their anesthetic regimen should be carefully monitored to ensure the best care and outcomes, according to recent—and independently developed—guidelines from the American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology and Intensive Care (ESAIC).
FAER is pleased to announce Sean Mackey, MD, PhD, Redlich Professor and Chief of the Division of Pain Medicine in the Department of Anesthesiology, Perioperative,…
Glucagon-like peptide-1 (GLP-1) receptor agonists are approved by the Food and Drug Administration for treatment of type 2 diabetes mellitus and cardiovascular risk reduction in…
Go behind the scenes with Dr. Fernandez in this podcast and ASA Monitor article (PDF) that describes her desire to “create a kind of professional…
On December 18, 2023, the Departments of Health and Human Services, Labor, and Treasury (the Departments) released the No Surprises Act Independent Dispute Resolution (IDR)…
Glucagon-like peptide-1 (GLP-1) receptor agonists are approved by the Food and Drug Administration for treatment of type 2 diabetes mellitus and cardiovascular risk reduction in…
Go behind the scenes with Dr. Fernandez in this podcast and ASA Monitor article (PDF) that describes her desire to “create a kind of professional…
Scope out PeRLS anesthesia-centric ACLS at the annual meeting. Engage in hands-on management of simulated perioperative emergencies, review current guidelines, and more. Keep care team…
With the growing popularity of medications like Ozempic® (semaglutide), Trulicity® (dulaglutide), and other glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes…
Glucagon-like peptide-1 (GLP-1) receptor agonists are approved by the Food and Drug Administration for treatment of type 2 diabetes mellitus and cardiovascular risk reduction in…
Medical Students: Scroll down the page to access all of the events. Click on each column heading to sort the events. Register by following the…
